RECRO PHARMA INC's ticker is REPH and the CUSIP is 75629F109. A total of 76 filers reported holding RECRO PHARMA INC in Q1 2021. The put-call ratio across all filers is 0.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $13,000 | -97.3% | 4,700 | -98.0% | 0.00% | -100.0% |
| Q3 2020 | $489,000 | +11.1% | 233,100 | +140.8% | 0.00% | 0.0% |
| Q2 2020 | $440,000 | +633.3% | 96,800 | +1208.1% | 0.00% | – |
| Q1 2020 | $60,000 | -55.6% | 7,400 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $135,000 | -25.0% | 7,400 | -54.9% | 0.00% | – |
| Q3 2019 | $180,000 | -69.2% | 16,400 | -71.5% | 0.00% | -100.0% |
| Q2 2019 | $584,000 | +63.6% | 57,500 | -5.7% | 0.00% | +50.0% |
| Q1 2019 | $357,000 | -34.1% | 61,000 | -20.2% | 0.00% | -33.3% |
| Q4 2018 | $542,000 | -16.5% | 76,400 | -16.3% | 0.00% | 0.0% |
| Q3 2018 | $649,000 | -3.3% | 91,300 | -31.8% | 0.00% | 0.0% |
| Q2 2018 | $671,000 | -4.1% | 133,800 | +110.4% | 0.00% | 0.0% |
| Q1 2018 | $700,000 | +241.5% | 63,600 | +186.5% | 0.00% | +200.0% |
| Q4 2017 | $205,000 | +485.7% | 22,200 | +455.0% | 0.00% | – |
| Q3 2017 | $35,000 | +25.0% | 4,000 | 0.0% | 0.00% | – |
| Q2 2017 | $28,000 | – | 4,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Engine Capital Management, LP | 1,104,546 | $11,233,000 | 5.38% |
| Broadfin Capital, LLC | 1,561,617 | $15,882,000 | 3.46% |
| Corsair Capital Management | 742,900 | $7,555,000 | 2.21% |
| NORTH RUN CAPITAL, LP | 315,338 | $3,207,000 | 2.18% |
| Fondren Management LP | 95,000 | $966,000 | 0.92% |
| Leap Investments LP | 25,611 | $260,000 | 0.35% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 213,002 | $2,166,000 | 0.30% |
| Campbell & CO Investment Adviser LLC | 38,989 | $397,000 | 0.18% |
| Opus Point Partners Management, LLC | 11,353 | $115,000 | 0.17% |
| Penn Capital Management Company, LLC | 149,946 | $1,525,000 | 0.15% |